Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 897 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Sarcoidosis
Interventions: adalimumab; Drug
Lead sponsor: Pariser, Robert J., M.D.; Other
Eligibility: 18 Years to 89 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Postmenopausal Women With Osteoporosis
Interventions: Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 4,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more

Conditions: Inflammation, Rheumatoid Arthritis
Interventions: NNC0109-0012, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 29
States / cities: Huntington Beach, California • La Mesa, California • Los Angeles, California + 26 more

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: TG4010, placebo; Biological · Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more

Conditions: Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura, Immune Thrombocytopenia
Interventions: Romiplostim, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 25
States / cities: Orange, California • San Diego, California • Washington D.C., District of Columbia + 21 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Phoenix, Arizona • Northbrook, Illinois • East Lansing, Michigan + 3 more

Conditions: Obesity, Overweight
Interventions: Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide), Placebo II (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 50
States / cities: Buena Park, California • Concord, California • Fresno, California + 42 more

Conditions: Menopause, Obesity, Abdominal, Aging, Weight Gain
Interventions: GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Meridian, Idaho + 6 more

Conditions: Cocaine Use Disorder
Interventions: Exenatide, Placebo; Drug
Lead sponsor: Christopher D. Verrico; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type II Diabetes Mellitus
Interventions: GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo; Drug · Other
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 61
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide Once Weekly, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 14,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 139
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Smoking Cessation, Weight Gain
Interventions: Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: DeBary, Florida • Sarasota, Florida • Canton, Georgia + 6 more

Conditions: Urinary Tract Infection
Interventions: Lactin-V, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metabolism and Nutrition Disorders, Overweight or Obesity
Interventions: NNC0165-1562, Semaglutide, Placebo (NNC0165-1562); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Diabetes Mellitus
Interventions: Exantide with Dapagliflozin, Exentide, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 76
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: SLS-005, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: LY3463251, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy, Vitamin D Deficiency
Interventions: ergocalciferol, placebo pill; Dietary Supplement · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: UBT251, UBT251 Placebo, Semaglutide, Semaglutide Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Fountain Valley, California • Long Beach, California + 21 more

Search by objective public record fields.

A Study of Adalimumab to Treat Sarcoidosis of the Skin

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Atacicept in Multiple Sclerosis Extension Study, Phase II

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Bioenergetic Effects of Aging and Menopause (BEAM)

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Exenatide For Reducing the Reinforcing Effects of Cocaine

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Exenatide for Smoking Cessation and Prevention of Weight Gain

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

A Study of LY3463251 in Healthy Participants

Vitamin D Deficiency in Adolescent Girls

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes